Rod McNeil
Rod McNeil is an independent medical journalist.
False
Advertisement
Shifting the AMD Burden-Benefit Balance
October 29, 2019
Aflibercept’s newly approved administration regime permits a reduction in intravitreal injection frequency – and recent clinical trial data (ALTAIR) suggest that extended interval dosing can sustain robust vision gains over 2 years
1 min read
Newsletters
Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.
False
Advertisement